Abstract:Phosphodiesterase-4 (PDE4) functions as a critical intracellular enzyme in immune cells and keratinocytes through the hydrolysis of cAMP. Inhibition of PDE4 has been considered as an effective therapeutic strategy in multiple inflammatory diseases. This study was intended to assess the anti-inflammatory effects of the PDE4 inhibitor, DC591017, both in vitro and in vivo. Murine RAW264.7 cells, BMDMs, BMDCs, and human NHEKs were incubated with DC591017 and then inflammatory mediators, intracellular cAMP and cAMP-mediated signaling pathways were analyzed. Carrageenan-induced acute inflammation in murine air pouches and rat paws, as well as imiquimod (IMQ)-induced psoriasis-like skin lesions were conducted to explore the therapeutic effects and underlying mechanisms of DC591017. We demonstrated herein that DC591017 suppressed the inflammatory responses of macrophages and DCs through promoting cAMP-dependent PKA-CREB signaling. Addition of forskolin functioned synergistically with DC591017, which could be blocked following H89 intervention or knockdown of PKA expression by siRNA transfection. In vivo, DC591017 treatment alleviated the leukocytes infiltration and secretion of inflammatory cytokines in murine air pouches and significantly attenuated carrageenan-induced paw swelling in rats. Moreover, we also illustrated that topical application of DC591017 ointment ameliorated IMQ-caused experimental psoriatic skin lesions, as evidenced by decreasing epidermal thickening and inflammatory infiltrations to inflamed skins. Consistently, DC591017 decreased expression of PDE4 isoforms and subsequently regulated PKA-CREB and NF-κB signaling. In brief, our study brought out a patent PDE4 inhibitor with robust anti-inflammation and provided the credible evidence in the treatment of patients with psoriasis.

Advances in the Study of PDE4 Inhibitors in Dermatological Disorders

Research Progress of Phosphodiesterase Inhibitors in Inflammatory Bowel Disease Treatment.

Progress in PDE4 Targeted Therapy for Inflammatory Diseases

Phosphodiesterase-4(PDE4) As a Target for Anti-Inflammatory Drug Discovery: Present and Prospect

PDE4 inhibitors: potential protective effects in inflammation and vascular diseases

Research progress of roflumilast in the treatment of chronic obstructive pulmonary disease

[Phosphodiesterase 4 inhibitors in dermatology : Role in the treatment of skin diseases]

Discover Natural Compounds As Potential Phosphodiesterase-4B Inhibitors Via Computational Approaches

Advances In The Development Of Phosphodiesterase-4 Inhibitors

Phosphodiesterase-4 Inhibition in the Management of Psoriasis

Targeting PDE4 as a promising therapeutic strategy in chronic ulcerative colitis through modulating mucosal homeostasis

Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors

Development of selective heterocyclic PDE4 inhibitors for treatment of psoriasis

Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis

Pharmacophore Modeling and Virtual Screening for the Discovery of New Type 4 Camp Phosphodiesterase (pde4) Inhibitors

Perspectives of PDE Inhibitor on Treating Idiopathic Pulmonary Fibrosis

Identification of Dihydrobenzofuran Neolignans as Novel PDE4 Inhibitors and Evaluation of Antiatopic Dermatitis Efficacy in DNCB-Induced Mice Model

Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials

Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment

DC591017, a Phosphodiesterase-4 (PDE4) Inhibitor with Robust Anti-Inflammation Through Regulating PKA-CREB Signaling.

PDE4D: A Multipurpose Pharmacological Target